Benzinga's M&A Chatter for Tuesday May 3, 2016


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


The following are the M&A deals, rumors and chatter circulating on Wall Street for Tuesday May 3, 2016:Microsoft Acquires Solair

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

The Deal:
Microsoft (NASDAQ: MSFT) has acquired Internet of Things company Solair, according to their official blog. Terms were not disclosed.Microsoft closed at $49.78 on Tuesday, down 1.64%. IMS Health, Quintiles to Merge in All-Stock TransactionThe Deal:
IMS Health Holdings, Inc. (NYSE: IMS) and Quintiles Transnational Holdings Inc. (NYSE: Q) announced Tuesday an agreement under which the companies will merge in an all-stock transaction. IMS Health shareholders will receive 0.384 shares of Quintiles common stock for each share of IMS Health common stock.The transaction is expected to close in H2 of 2016. IMS Health closed at $25.92 on Tuesday, down 3.5%. Quintiles closed at $67.46 down 2.37%

Want Private Access to Benzinga Analyst?

Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.


Clorox to Acquire Renew LifeThe Deal:
The Clorox Company (NYSE: CLX) today announced the acquisition of dietary health brand Renew Life. Terms were not disclosed.Clorox closed at $129.43 on Tuesday, up 2%.Pfizer Said to have Approached Medivation Regarding TakeoverThe Rumor:
Shares of Medivation (NASDAQ: MDVN) spiked up to $60.50 after-hours as Reuters reported that Pfizer (NYSE: PFE) has made a takeover approach, according to sources. Late last month Sanofi's (NYSE: SNY) $52.50 per share offer was rejected by Medivation's Board.AstraZeneca (NYSE: AZN) and Novartis (NYSE: NVS) are also said to have expressed interest in the maker of prostate cancer drug Xtandi.Medivation closed the regular session at $57.52 on Tuesday, down $0.49.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: NewsRumorsM&AMovers